FY2024 EPS Estimates for Personalis Cut by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL - Free Report) - HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Personalis in a note issued to investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.37) for the year, down from their prior forecast of ($1.01). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Personalis' Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.46) EPS and FY2027 earnings at ($0.04) EPS.

Other research analysts have also issued research reports about the company. Needham & Company LLC restated a "buy" rating and set a $7.25 price objective on shares of Personalis in a research report on Thursday. BTIG Research increased their price target on Personalis from $5.50 to $7.00 and gave the company a "buy" rating in a research note on Friday, August 16th.

Personalis Trading Up 8.1 %

PSNL traded up $0.37 during trading on Monday, hitting $4.92. 1,039,733 shares of the company traded hands, compared to its average volume of 718,581. The company has a market cap of $261.15 million, a PE ratio of -2.84 and a beta of 1.94. The stock's 50-day simple moving average is $5.13 and its two-hundred day simple moving average is $3.37. Personalis has a 1 year low of $1.00 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $25.71 million during the quarter, compared to the consensus estimate of $20.67 million. During the same quarter in the previous year, the company earned ($0.51) earnings per share.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Personalis during the third quarter valued at approximately $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock valued at $81,000 after acquiring an additional 4,504 shares during the period. Public Employees Retirement System of Ohio bought a new position in Personalis in the 1st quarter valued at $29,000. International Assets Investment Management LLC increased its stake in Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock worth $113,000 after purchasing an additional 17,082 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Personalis during the first quarter worth $41,000. 61.91% of the stock is owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.